Treatment with FLT3 inhibitor in patients with FLT3‐mutated acute myeloid leukemia is associated with development of secondary FLT3–tyrosine kinase domain mutations

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|14|2142-2149

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.14, 2014-07, pp. : 2142-2149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sorafenib Treatment in 13 Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations in Combination with Chemotherapy or as Monotherapy

By  

Acta Haematologica, Vol. 124, Iss. 3, 2010-10 ,pp. : 153-159

Karger

Access to resources Recommend Favorite

Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 306-314

John Wiley & Sons Inc

Access to resources Recommend Favorite

Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 1065-1070

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Surface Molecular Signature of Leukemic Cells Is Associated with NPM1 Mutations and FLT3-ITD in Patients with de novo Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 3, 2013-10 ,pp. : 148-152

Karger

Access to resources Recommend Favorite